Literature DB >> 18461345

Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).

Serra Kamer1, Qing Ren, Adam P Dicker.   

Abstract

PURPOSE/OBJECTIVE(S): Cervical cancer is one of the deadliest cancers in women with a death toll of 230,000 worldwide each year, nearly 80% in developing countries. Radiotherapy (RT) is a major treatment modality for advanced cervical cancer but the local relapse rate is 30-44% in patients treated with RT alone and 19-25% in patients treated with concurrent chemoradiotherapy. Previous studies have shown that the transcription factor NF-kappaB is constitutively expressed in human cervical squamous cell carcinomas. NF-kappaB activation also contributes to the resistance of cervical cancer cells to apoptosis induced by chemotherapeutic agents and radiation. Therefore, inhibition of NF-kappaB in tumor cells may render them more sensitive to chemo/radiation therapies. The objective of this study is to investigate the potential of radiosensitization of NF-kappaB inhibition by Velcade in human cervical cancer cell lines.
MATERIALS AND METHODS: We used the human cervical cancer cell lines HeLa and SiHa. Both are highly radioresistant and chemoresistant as compared to other cervical cancer cell lines. These cells had been treated with Velcade before they were irradiated with different doses of ionizing radiation. MTT metabolic assays and clonogenic cell survival assays were performed to evaluate the effects of Velcade on radiation resistance.
RESULTS: Inhibition of NF-kappaB by Velcade alone decreased metabolic potential (MTT) and clonogenic survival in SiHa, but not in HeLa cells. Furthermore, pre-treatment of SiHa, but not HeLa cells with Velcade enhanced radiation sensitivity.
CONCLUSIONS: Inhibition of NF-kappaB by the proteasome inhibitor Velcade enhances radiosensitivity of certain human cervical carcinoma cancer cells in vitro. These results raise the possibility that inhibition of NF-kappaB will result in radiosensitization only in those tumor cells which are more dependent on NF-kappaB for their metabolism and survival, however, the radiosensitivity of "NF-kappaB independent" cells are not likely influenced by it.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461345     DOI: 10.1007/s00404-008-0667-7

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

Review 1.  Targeting inflammatory pathways for tumor radiosensitization.

Authors:  Amit Deorukhkar; Sunil Krishnan
Journal:  Biochem Pharmacol       Date:  2010-06-30       Impact factor: 5.858

2.  Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation.

Authors:  Amit K Garg; Anuja Jhingran; Ann H Klopp; Bharat B Aggarwal; Ajai B Kunnumakkara; Russell R Broadus; Patricia J Eifel; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

3.  Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

Authors:  Dongping Wei; Meredith A Morgan; Yi Sun
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 4.  Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Authors:  Anthony R Mato; Tatyana Feldman; André Goy
Journal:  Oncologist       Date:  2012-05-07

Review 5.  Therapy of human papillomavirus-related disease.

Authors:  Peter L Stern; Sjoerd H van der Burg; Ian N Hampson; Thomas R Broker; Alison Fiander; Charles J Lacey; Henry C Kitchener; Mark H Einstein
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

6.  Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG132.

Authors:  Yoko Matsumoto; Yuichiro Miyamoto; Horacio Cabral; Yu Matsumoto; Kazunori Nagasaka; Shunsuke Nakagawa; Tetsu Yano; Daichi Maeda; Katsutoshi Oda; Kei Kawana; Nobuhiro Nishiyama; Kazunori Kataoka; Tomoyuki Fujii
Journal:  Cancer Sci       Date:  2016-04-27       Impact factor: 6.716

7.  Rab12 Promotes Radioresistance of HPV-Positive Cervical Cancer Cells by Increasing G2/M Arrest.

Authors:  Yujie Huang; Yonghao Tian; Wenhao Zhang; Ruijuan Liu; Weifang Zhang
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

8.  Novel synthetic monoketone transmute radiation-triggered NFκB-dependent TNFα cross-signaling feedback maintained NFκB and favors neuroblastoma regression.

Authors:  Sheeja Aravindan; Mohan Natarajan; Vibhudutta Awasthi; Terence S Herman; Natarajan Aravindan
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

9.  Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.

Authors:  Colin Rae; Mathias Tesson; John W Babich; Marie Boyd; Robert J Mairs
Journal:  EJNMMI Res       Date:  2013-11-13       Impact factor: 3.138

10.  In vivo antitumor activity of liposome‑plasmid DNA encoding mutant survivin‑T34A in cervical cancer.

Authors:  Fang Qiu; Xia Zhao
Journal:  Mol Med Rep       Date:  2018-05-11       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.